Pulmonary Arterial Hypertension
Conditions
Brief summary
This proof-of-concept study is designed as a Phase 2, multicenter, randomized, double-blind, placebo controlled study comparing ubenimex with placebo in patients with pulmonary arterial hypertension (PAH) (World Health Organization \[WHO\] Group 1) and have a WHO/New York Heart Association (NYHA) Functional Classification (WHO/NYHA-FC) of II or III.
Detailed description
Ubenimex is being developed for the treatment of PAH (WHO Group 1) to improve exercise capacity and delay clinical worsening. This proof-of-concept study is designed as a Phase 2, multicenter, randomized, double-blind, placebo controlled study comparing ubenimex with placebo in patients with PAH (WHO Group 1) and have a WHO/NYHA Functional Classification (WHO/NYHA-FC) of II or III. The Primary Objectives for the study are: * To evaluate the efficacy of ubenimex in patients with PAH (WHO Group 1). * To evaluate the safety and tolerability of ubenimex in patients with WHO Group 1 PAH.
Interventions
DRUGubenimex
OTHERplacebo
Sponsors
Eiger BioPharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female, 18-75 years old. 2. Has a diagnosis of WHO Group 1 PAH. 3. Right heart catheterization performed at Screening with results that are: 1. Mean pulmonary arterial pressure ≥25 mmHg (at rest) and 2. Pulmonary venous hypertension (measured as pulmonary capillary wedge pressure (PCWP) ≤15 mmHg. If PCWP is not available, then mean left atrial pressure or left ventricular end-diastolic pressure ≤15 mmHg in the absence of left atrial obstruction. and 3. Pulmonary vascular resistance (PVR) ≥300 dyn•s/cm5 (3.75 Wood units) 4. Has WHO/NYHA-FC of II or III. 5. Be on stable dose of at least one of the following PAH-specific therapies: endothelin receptor antagonist, an agent acting on the nitric oxide pathway (phosphodiesterase type 5 inhibitor or soluble guanylate cyclase stimulator), and/or a prostacyclin or prostacyclin analog. 6. Has a 6-minute walk distance that is ≥150 and ≤500 meters. 7. Have a ventilation-perfusion scan that rules out thromboembolic disease.
Exclusion criteria
Exclusions Related to Cardiovascular Disease 1. History of uncontrolled hypertension 2. Persistent hypotension at Screening. 3. Evidence or history of left-sided heart disease and/or clinically significant cardiac disease in which pulmonary hypertension is more likely WHO Group 2. 4. Acute decompensated heart failure within 1 month of Screening. 5. Recent initiation (\<8 weeks from Screening) or planned initiation of cardiopulmonary rehabilitation exercise program. Exclusions Related to Pulmonary Disease 6. Newly diagnosed with PAH and not on PAH-specific therapy. 7. Pulmonary hypertension due to: 1. Uncorrected congenital systemic-to-pulmonary shunt. 2. Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 3. Persistent pulmonary hypertension of the newborn 4. WHO clinical classification Groups 2-5 8. Evidence of significant airway and/or parenchymal lung disease. 9. Chronic infection related to tuberculosis or fungal or mycobacterial disease. Exclusions Based on Other Medical Conditions 10. Chronic infections including, but not limited to tuberculosis (TB), hepatitis B virus (HBV) or hepatitis C virus (HCV). 11. History of portal hypertension or chronic liver disease, including positive serology for infection with HCV and/or HBV. 12. Evidence of active infection requiring intravenous or oral antibiotics within 4 weeks of Screening. 13. Body mass index ≥35.0 at Screening. 14. History of obstructive sleep apnea. 15. History of malignancy within the last 5 years, except nonmelanoma skin cancer and cervical carcinoma in situ treated with curative intent. 16. Neuropsychiatric disorders/symptoms or psychological conditions. 17. Pregnancy or breast-feeding 18. Prior treatment with B cell or lymphocyte-depleting agents (eg, rituximab, Campath) Exclusions Based on Concomitant Medication Use 19. Concurrent regular use of another leukotriene pathway inhibitor, including over-the-counter medications or herbal remedies. Exclusions Based on Laboratory Values 20. Significant/chronic renal insufficiency. 21. Transaminases (alanine transaminase, aspartate transaminase) levels \>3 × upper limit of normal (ULN) and/or bilirubin level \>2 × ULN. 22. Absolute neutrophil count \<1500 mm3. 23. Hemoglobin concentration \<9 g/dL at Screening. 24. Hepatic dysfunction as defined by Child-Pugh Class B or C
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Pulmonary Vascular Resistance (PVR) | Baseline to Week 24 | Change from Baseline at End of Treatment in PVR Using Worst Case Imputation in the Modified Intent to Treat Population. PVR was assessed by hemodynamic measurements obtained via right heart catheterization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in 6-minute Walk Distance (6MWD) | Baseline to Week 24 | Change in exercise capacity from baseline to Week 24 as determined by the 6MWD |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Ubenimex ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
ubenimex | 41 |
| Placebo placebo capsules TID, administered orally for a total of 24 weeks
placebo | 20 |
| Total | 61 |
Baseline characteristics
| Characteristic | Ubenimex | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 49.9 years | 53.0 years | 50.9 years |
| Mean pulmonary vascular resistance (PVR) | 649.9 dyn•s/cm^5 STANDARD_DEVIATION 315.8 | 624.4 dyn•s/cm^5 STANDARD_DEVIATION 217.1 | 641.57 dyn•s/cm^5 STANDARD_DEVIATION 217.1 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 2 Participants | 7 Participants |
| Race (NIH/OMB) White | 36 Participants | 18 Participants | 54 Participants |
| Sex: Female, Male Female | 36 Participants | 15 Participants | 51 Participants |
| Sex: Female, Male Male | 5 Participants | 5 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 41 | 0 / 20 |
| other Total, other adverse events | 39 / 41 | 18 / 20 |
| serious Total, serious adverse events | 9 / 41 | 2 / 20 |
Outcome results
Primary
Change in Pulmonary Vascular Resistance (PVR)
Change from Baseline at End of Treatment in PVR Using Worst Case Imputation in the Modified Intent to Treat Population. PVR was assessed by hemodynamic measurements obtained via right heart catheterization.
Time frame: Baseline to Week 24
Population: Modified Intent to Treat Population: i.e., all randomized patients who received at least one dose of study drug and had a baseline assessment for the respective endpoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ubenimex | Change in Pulmonary Vascular Resistance (PVR) | 73.1 dyn.sec/cm5 | Standard Deviation 271.6 |
| Placebo | Change in Pulmonary Vascular Resistance (PVR) | 46.6 dyn.sec/cm5 | Standard Deviation 256.8 |
Secondary
Change in 6-minute Walk Distance (6MWD)
Change in exercise capacity from baseline to Week 24 as determined by the 6MWD
Time frame: Baseline to Week 24
Population: Modified intention-to-treat population: i.e., all randomized patients who received at least one dose of study drug and had a baseline assessment for the respective endpoint.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Ubenimex | Change in 6-minute Walk Distance (6MWD) | -20.0 meters | Standard Error 12.79 |
| Placebo | Change in 6-minute Walk Distance (6MWD) | 4.2 meters | Standard Error 17.38 |